Professor Spencer Collis

All publications

Journal articles

• Zhao F, Rominiyi O, Collis S, Jiang H & Gomez-Roman N (2025) P12.58.A ROLE OF IL-33/ST2 AXIS IN GLIOBLASTOMA DEVELOPMENT AND ITS RESPONSE TO TREATMENT. Neuro-Oncology, 27(Supplement_3), iii130-iii130.
• Dada OE, Chisango Z, Nkansah-Poku KAB, Sowah M, Williams S, Rodrigues ACLF, Duru O, Myers M, Shlobin N, Ushewokunze S , Omoruyi S et al (2025) RACE AND ‘OMIC’ DATA IN GLIOMA: A SYSTEMATIC REVIEW OF CONTEMPORARY RESEARCH TO EXPLORE THE DIGITAL DIVIDE. Neuro-Oncology, 27(Supplement_2), ii29-ii29.
• Lefley DV, Jones CG, Zhou J, Bryant HE, Collis SJ, Down JM, Brown JE & Ottewell PD (2025) ATM inhibition increases the anti-tumor efficacy of radium-223 (Ra-223) against prostate cancer bone metastasis in preclinical models. JBMR Plus, 9(10). View this article in WRRO
• Cheng VWT, Vaughn-Beaucaire P, Shaw GC, Kriegs M, Droop A, Psakis G, Mittelbronn M, Humphries M, Esteves F, Hayes J , Cockle JV et al (2025) ARHGAP12 and ARHGAP29 exert distinct regulatory effects on switching between two cell morphological states through GSK-3 activity. Cell Reports, 44(3), 115361-115361.
• Dada OE, Chisango Z, Nkansah-Poku KAB, Sowah MN, Rodrigues ACLF, Duru O, Myers M, Williams ST, Ushewokunze S, Collis SJ , Shlobin NA et al (2025) Race and ‘omic’ data in glioma: a systematic review of contemporary research to explore the digital divide. Neuro-Oncology Practice, 12(4), 585-599. View this article in WRRO
• Zhao A, Maple L, Jiang J, Myers KN, Jones CG, Gagg H, McGarrity-Cottrell C, Rominiyi O, Collis SJ, Wells G , Rahman M et al (2024) SENP3-FIS1 axis promotes mitophagy and cell survival under hypoxia. Cell Death & Disease, 15(12). View this article in WRRO
• Lad N, Jones CG, Myers KN, McGarrity-Cottrell CL, Finegan KG, Rominiyi O & Collis SJ (2024) DNAR-05. VALIDATING THE ERK5 PROTAC OS11 AS A POTENTIAL NOVEL THERAPEUTIC INEX VIVO GLIOMA STEM CELL MODELS OF INTRATUMOURAL HETEROGENEITY AND RESIDUAL DISEASE. Neuro-Oncology, 26(Supplement_8), viii118-viii118.
• Jones C, Collis S, Rominiyi O, Myers K, Vanderlinden A & McGarrity-Cottrell C (2024) DNAR-04. TUMOUR TREATING FIELDS (TTFIELDS) AND DNA DAMAGE RESPONSE (DDR) INHIBITORS ENHANCE GLIOMA CELL DEATH THROUGH CHEMO-/RADIOSENSITISATION. Neuro-Oncology, 26(Supplement_8), viii117-viii118.
• Rominiyi O, McGarrity-Cottrell C, Myers KN, Jones CG, Wosnitzka K, Williams ST, Vanderlinden A, Antohi A-G, Gomez-Roman N, Chalmers AJ , Sinha S et al (2024) Ex-vivo models of post-surgical residual disease in human glioblastoma [version 1; peer review: awaiting peer review]. F1000Research, 13. View this article in WRRO
• Jones CG, Vanderlinden A, Rominiyi O & Collis SJ (2024) Development and optimisation of Tumour Treating Fields (TTFields) delivery within 3D primary glioma stem cell-like models of spatial heterogeneity. Cancers, 16(5). View this article in WRRO
• Derby S, Dutton L, Strathdee KE, Stevenson K, Koessinger A, Jackson M, Tian Y, Yu W, Mclay K, Misquitta J , Alsharif S et al (2024) Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis. Neuro-Oncology, 26(4), 625-639. View this article in WRRO
• Gagg H, Williams ST, Conroy S, Myers KN, McGarrity-Cottrell C, Jones C, Helleday T, Rantala J, Rominiyi O, Danson SJ , Collis SJ et al (2024) Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000research, 12.
• Vanderlinden A, Jones CG, Myers KN, Rominiyi O & Collis SJ (2023) DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells. British Journal of Cancer, 129(11), 1829-1840.
• McGarrity-Cottrell C, Myers K, Dunning M, Bagga V, Sinna S, Al-Tamimi Y, Rominiyi O & Collis S (2023) DEfiNING SPATIAL HETEROGENEITY OF A NOVEL LIVING BIOBANK OF POST-SURGICAL RESIDUAL GLIOBLASTOMA TO DEVELOP STRATEGIES FOR TARGETED THERAPY. Neuro-Oncology, 25(Supplement_3), iii14-iii14.
• Patel P, Alghamdi A, Shaw G, Legge C, Glover M, Freeman D, Hodgetts H, Wilson E, Howard F, Staniland S , Kennerley AJ et al (2023) Development of a personalised device for systemic magnetic drug targeting to brain tumours. Nanotheranostics, 7(1), 102-116. View this article in WRRO
• McGarrity - Cottrell C, Myers K, Wang D, Dunning M, Bagga V, Al-Tamimi Y, Sinha S, Rominiyi O & Collis S (2022) STEM-02. GENERATION AND CHARACTERISATION OF A LIVING BIOBANK OF POST-SURGICAL RESIDUAL GLIOBLASTOMA TO IDENTIFY NOVEL THERAPEUTIC TARGETS. Neuro-Oncology, 24(Supplement_7), vii31-vii31.
• Vanderlinden A, Rominiyi O, Collis S, Jones C, Myers K & McGarrity - Cottrell C (2022) DNAR-12. COMBINING TUMOUR TREATING FIELDS WITH THERAPEUTIC DNA DAMAGE RESPONSE INHIBITORS TO INCREASE POTENCY IN HIGH-GRADE GLIOBLASTOMAS USING CLINICALLY RELEVANT EX-VIVO GLIOMA STEM CELL MODELS. Neuro-Oncology, 24(Supplement_7), vii93-vii93.
• Williams ST, Wells G, Conroy S, Gagg H, Allen R, Rominiyi O, Helleday T, Hullock K, Pennington CEW, Rantala J , Collis SJ et al (2022) Precision oncology using ex vivo technology: a step towards individualised cancer care?. Expert Reviews in Molecular Medicine, 24. View this article in WRRO
• Rominiyi O & Collis SJ (2022) DDRugging glioblastoma: understanding and targeting the DNA damage response to improve future therapies.. Molecular Oncology, 16(1), 11-41. View this article in WRRO
• Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y & Collis SJ (2021) Tumour treating fields therapy for glioblastoma: current advances and future directions (vol 124, pg 697, 2020). BRITISH JOURNAL OF CANCER, 125(4), 623-623.
• Rominiyi O, Vanderlinden A, Myers K, Gomez-Roman N, Dar D, Bagga V, Jellinek DA, Chalmers AJ, Carroll TA, Al-Tamimi Y & Collis SJ (2021) O2: TOWARDS A LIVING BIOBANK OF SURGICALLY-RELEVANT 3-DIMENSIONAL GLIOBLASTOMA STEM CELL MODELS TO EVALUATE NOVEL THERAPEUTICS AND INTERROGATE INTRATUMOURAL HETEROGENEITY. British Journal of Surgery, 108(Supplement_1).
• Carmell N, Rominiyi O, Myers KN, McGarrity-Cottrell C, Vanderlinden A, Lad N, Perroux-David E, El-Khamisy SF, Fernando M, Finegan KG , Brown S et al (2021) Identification and validation of ERK5 as a DNA damage modulating drug target in glioblastoma. Cancers, 13(5). View this article in WRRO
• Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y & Collis SJ (2021) Tumour treating fields therapy for glioblastoma: current advances and future directions.. Br J Cancer, 124(4), 697-709.
• Bennett LG, Wilkie AM, Antonopoulou E, Ceppi I, Sanchez A, Vernon EG, Gamble A, Myers KN, Collis SJ, Cejka P & Staples CJ (2020) MRNIP is a replication fork protection factor.. Sci Adv, 6(28), eaba5974.
• O'Regan L, Barone G, Adib R, Woo CG, Jeong HJ, Richardson EL, Richards MW, Muller PAJ, Collis SJ, Fennell DA , Choi J et al (2020) EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7.. J Cell Sci, 133(9).
• Rominiyi O, Myers K, Gomez-Roman N, Lad N, Dar D, Jellinek D, Chalmers A, Carroll T, Chen B, Al-Tamimi Y & Collis S (2019) RDNA-12. THE FANCONI ANAEMIA (FA) PATHWAY AND GLIOBLASTOMA: A NEW FOUNDATION FOR DNA DAMAGE RESPONSE TARGETED COMBINATIONS. Neuro-Oncology, 21(Supplement_6), vi209-vi209.
• Rominiyi O, Myers K, Vanderlinden A, Dar D, Bagga V, Gomez-Roman N, Jellinek D, Carroll T, Chalmers A, Al-Tamimi Y & Collis S (2019) TMOD-39. EX-VIVO 3-DIMENSIONAL MODELS OF POST-SURGICAL RESIDUAL DISEASE IN HUMAN GLIOBLASTOMA. Neuro-Oncology, 21(Supplement_6), vi271-vi271.
• Rominiyi O, Al-Tamimi Y & Collis SJ (2019) The 'Ins and Outs' of Early Preclinical Models for Brain Tumor Research: Are They Valuable and Have We Been Doing It Wrong?. Cancers (Basel), 11(3).
• Carmell N, Brown S, Khamisy S & Collis S (2018) NOVEL DRUG TARGETS TO AUGMENT TEMOZOLOMIDE SENSITIVITY IN HIGH-GRADE BRAIN TUMOURS. NEURO-ONCOLOGY, 20, 346-346.
• Rominiyi O, Gomez-Roman N, Lad N, Al-Tamimi Y, Jellinek DA, Chalmers AJ, Carroll TA, Chen B & Collis SJ (2018) P04.74 Preclinical evaluation of combinations targeting the DNA damage response in 2D and 3D models of glioblastoma stem cells. Neuro-Oncology, 20(suppl_3), iii297-iii297.
• Barone G, Arora A, Ganesh A, Abdel-Fatah T, Moseley P, Ali R, Chan SY, Savva C, Schiavone K, Carmell N , Myers KN et al (2018) The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response.. Oncotarget, 9(50), 29508-29524.
• Myers KN, Barone G, Ganesh A, Staples CJ, Howard AE, Beveridge RD, Maslen S, Skehel JM & Collis SJ (2016) The bornavirus-derived human protein EBLN1 promotes efficient cell cycle transit, microtubule organisation and genome stability.. Sci Rep, 6, 35548.
• Barone G, Staples CJ, Ganesh A, Patterson KW, Bryne DP, Myers KN, Patil AA, Eyers CE, Maslen S, Skehel JM , Eyers PA et al (2016) Human CDK18 promotes replication stress signaling and genome stability.. Nucleic Acids Res, 44(18), 8772-8785.
• Staples CJ, Barone G, Myers KN, Ganesh A, Gibbs-Seymour I, Patil AA, Beveridge RD, Daye C, Beniston R, Maslen S , Ahel I et al (2016) MRNIP/C5orf45 Interacts with the MRN Complex and Contributes to the DNA Damage Response.. Cell Rep, 16(10), 2565-2575.
• Johnson CA & Collis SJ (2016) Ciliogenesis and the DNA damage response: a stressful relationship.. Cilia, 5, 19.
• Patil AA, Hua P, Sellwood MA, Jellinek DA, Carroll TA, Chen B & Collis SJ (2015) OP21IDENTIFICATION OF NOVEL SMALL MOLECULE INHIBITORS OF THE FANCONI ANAEMIA DNA REPAIR PATHWAY AS A MEANS TO SENSITISES GLIOBLASTOMAS TO CHEMOTHERAPEUTIC AGENTS. Neuro-Oncology, 17(suppl 8), viii20.1-viii20.
• Beveridge RD, Staples CJ, Patil AA, Myers KN, Maslen S, Skehel JM, Boulton SJ & Collis SJ (2014) The leukemia-associated Rho guanine nucleotide exchange factor LARG is required for efficient replication stress signaling.. Cell Cycle, 13(21), 3450-3459.
• Patil AA, Sayal P, Depondt M-L, Beveridge RD, Roylance A, Kriplani DH, Myers KN, Cox A, Jellinek D, Fernando M , Carroll TA et al (2014) FANCD2 re-expression is associated with glioma grade and chemical inhibition of the Fanconi Anaemia pathway sensitises gliomas to chemotherapeutic agents.. Oncotarget, 5(15), 6414-6424.
• Staples CJ, Myers KN, Beveridge RDD, Patil AA, Howard AE, Barone G, Lee AJX, Swanton C, Howell M, Maslen S , Skehel JM et al (2014) Ccdc13 is a novel human centriolar satellite protein required for ciliogenesis and genome stability.. J Cell Sci, 127(Pt 13), 2910-2919.
• Staples CJ, Myers KN, Beveridge RDD, Patil AA, Lee AJX, Swanton C, Howell M, Boulton SJ & Collis SJ (2013) The centriolar satellite protein Cep131 is important for genome stability. Development, 140(2), e207-e207.
• Staples CJ, Myers KN, Beveridge RDD, Patil AA, Lee AJX, Swanton C, Howell M, Boulton SJ & Collis SJ (2012) The centriolar satellite protein Cep131 is important for genome stability.. J Cell Sci, 125(Pt 20), 4770-4779.
• Horejsí Z, Takai H, Adelman CA, Collis SJ, Flynn H, Maslen S, Skehel JM, de Lange T & Boulton SJ (2010) CK2 phospho-dependent binding of R2TP complex to TEL2 is essential for mTOR and SMG1 stability.. Mol Cell, 39(6), 839-850.
• Adamo A, Collis SJ, Adelman CA, Silva N, Horejsi Z, Ward JD, Martinez-Perez E, Boulton SJ & La Volpe A (2010) Preventing nonhomologous end joining suppresses DNA repair defects of Fanconi anemia.. Mol Cell, 39(1), 25-35.
• Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MSQ, Wissing MD, Hedayati M, Shabbeer S, Mendonca J, Deangelis J, Marchionni L , Lin J et al (2010) Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor.. PLoS One, 5(6), e11208.
• Collis SJ & Boulton SJ (2010) FANCM: fork pause, rewind and play.. EMBO J, 29(4), 703-705.
• Horejŝí Z, Collis SJ & Boulton SJ (2009) FANCM-FAAP24 and HCLK2: roles in ATR signalling and the Fanconi anemia pathway.. Cell Cycle, 8(8), 1133-1137.
• Youds JL, Barber LJ, Ward JD, Collis SJ, O'Neil NJ, Boulton SJ & Rose AM (2008) DOG-1 is the Caenorhabditis elegans BRIP1/FANCJ homologue and functions in interstrand cross-link repair.. Mol Cell Biol, 28(5), 1470-1479.
• Collis SJ, Ciccia A, Deans AJ, Horejsí Z, Martin JS, Maslen SL, Skehel JM, Elledge SJ, West SC & Boulton SJ (2008) FANCM and FAAP24 function in ATR-mediated checkpoint signaling independently of the Fanconi anemia core complex.. Mol Cell, 32(3), 313-324.
• Barber LJ, Youds JL, Ward JD, McIlwraith MJ, O'Neil NJ, Petalcorin MIR, Martin JS, Collis SJ, Cantor SB, Auclair M , Tissenbaum H et al (2008) RTEL1 maintains genomic stability by suppressing homologous recombination.. Cell, 135(2), 261-271.
• Marples B & Collis SJ (2008) Low-dose hyper-radiosensitivity: past, present, and future.. Int J Radiat Oncol Biol Phys, 70(5), 1310-1318.
• Krueger SA, Collis SJ, Joiner MC, Wilson GD & Marples B (2007) Transition in survival from low-dose hyper-radiosensitivity to increased radioresistance is independent of activation of ATM Ser1981 activity.. Int J Radiat Oncol Biol Phys, 69(4), 1262-1271.
• Collis SJ & Boulton SJ (2007) Emerging links between the biological clock and the DNA damage response.. Chromosoma, 116(4), 331-339.
• Collis SJ, Barber LJ, Clark AJ, Martin JS, Ward JD & Boulton SJ (2007) HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability.. Nat Cell Biol, 9(4), 391-401.
• Qian DZ, Kachhap SK, Collis SJ, Verheul HMW, Carducci MA, Atadja P & Pili R (2006) Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. CANCER RES, 66(17), 8814-8821.
• Collis SJ, Barber LJ, Ward JD, Martin JS & Boulton SJ (2006) C. elegans FANCD2 responds to replication stress and functions in interstrand cross-link repair.. DNA Repair (Amst), 5(11), 1398-1406.
• Collis SJ, DeWeese TL, Jeggo PA & Parker AR (2005) The life and death of DNA-PK.. Oncogene, 24(6), 949-961.
• Collis SJ, Schwaninger JM, Ntambi AJ, Keller TW, Nelson WG, Dillehay LE & Deweese TL (2004) Evasion of early cellular response mechanisms following low level radiation-induced DNA damage.. J Biol Chem, 279(48), 49624-49632.
• Collis SJ & DeWeese TL (2004) Enhanced radiation response through directed molecular targeting approaches.. Cancer Metastasis Rev, 23(3-4), 277-292.
• Collis SJ, Neutzel S, Thompson TL, Swartz MJ, Dillehay LE, Collector MI, Sharkis SJ & DeWeese TL (2004) Hematopoietic progenitor stem cell homing in mice lethally irradiated with ionizing radiation at differing dose rates.. Radiat Res, 162(1), 48-55.
• Marples B, Wouters BG, Collis SJ, Chalmers AJ & Joiner MC (2004) Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiation-damaged G2-phase cells.. Radiat Res, 161(3), 247-255.
• Collis SJ, Khater K & DeWeese TL (2003) Novel therapeutic strategies in prostate cancer management using gene therapy in combination with radiation therapy.. World J Urol, 21(4), 275-289.
• Collis SJ, Swartz MJ, Nelson WG & DeWeese TL (2003) Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors.. Cancer Res, 63(7), 1550-1554.
• Collis SJ, Ketner GW, Hicks JL, Nelson WG, Demarzo AM & Deweese TL (2003) Expression of the DNA-PK binding protein E4-34K fails to confer radiation sensitivity to mammalian cells.. Int J Radiat Biol, 79(1), 53-60.
• Collis SJ, Sangar VK, Tighe A, Roberts SA, Clarke NW, Hendry JH & Margison GP (2002) Development of a novel rapid assay to assess the fidelity of DNA double-strand-break repair in human tumour cells.. Nucleic Acids Res, 30(2), E1.
• Collis SJ, Tighe A, Scott SD, Roberts SA, Hendry JH & Margison GP (2001) Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells.. Nucleic Acids Res, 29(7), 1534-1538.
• Gagg H, Williams ST, Conroy S, Myers KN, McGarrity-Cottrell C, Jones C, Helleday T, Rantala J, Rominiyi O, Danson SJ , Collis SJ et al () Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients. F1000Research, 12, 954-954.

Book chapters

• Marples B, Krueger SA, Collis SJ & Joiner MC (2008) Low dose hyper-radiosensitivity: A historical perspective, Targeted Radionuclide Tumor Therapy Biological Aspects (pp. 329-347).
• Collis SJ (2007) Molecular targeting of DNA repair: A means to improve therapeutic index, New Research on DNA Repair (pp. 1-37).

Conference proceedings

• Lefley D, Jones C, Danson S, Bryant H, Collis S, Brown J & Ottewell P (2023) Addition of ATM Inhibitors to Radium223 Reduces Prostate Cancer Bone Metastases In Vivo. JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 38 (pp 214-215)
• Gagg H, Williams S, Rominiyi O, Danson S, Collis S & Wells G (2023) DEVELOPMENT OF GLIEXP; A HIGH-THROUGHPUT EX VIVO DRUG SCREENING PLATFORM FOR GLIOBLASTOMA. Neuro-Oncology, Vol. 25(Supplement_3) (pp iii5-iii6)
• McGarrity-Cottrell C, Myers K, Wang D, Dunning M, Bagga V, Al-Tamimi Y, Sinha S, Rominiyi O & Collis S (2022) GENERATION AND CHARACTERISATION OF A LIVING BIOBANK OF POST-SURGICAL RESIDUAL GLIOBLASTOMA TO IDENTIFY NOVEL THERAPEUTIC TARGETS.. NEURO-ONCOLOGY, Vol. 24 (pp 31-31)
• Vanderlinden A, Rominiyi O, Collis S, Jones C, Myers K & McGarrity-Cottrell C (2022) COMBINING TUMOUR TREATING FIELDS WITH THERAPEUTIC DNA DAMAGE RESPONSE INHIBITORS TO INCREASE POTENCY IN HIGH-GRADE GLIOBLASTOMAS USING CLINICALLY RELEVANT EX-VIVO GLIOMA STEM CELL MODELS.. NEURO-ONCOLOGY, Vol. 24 (pp 93-93)
• Gagg H, Williams S, Allen R, Conroy S, Rominiyi O, Wells G, Rantala J, Danson S, Helleday T & Collis S (2022) F-1286: Ex vivo-led drug discovery in glioblastoma. Brain Tumor Research and Treatment, Vol. 10(Suppl) (pp s240). Seoul, Korea, 24 March 2022 - 24 March 2022. View this article in WRRO
• Rominiyi O, Vanderlinden A, Clenton SJ, Bridgewater C, Al-Tamimi Y & Collis S (2022) Tumour treating fields (TTFields) therapy for glioblastoma: a quantitative and qualitative summary of research and advances in our understanding. WFNOS 2022 Abstract Book (pp S251-S251), 24 March 2022 - 27 March 2022.
• Zizzo C, Keating J, Sinha S, Al-Tamimi Y, Dyson B, Collis S & Rominiyi O (2022) Patient-centric design of a neuro-oncology research primer to enhance communication and support of specimen donation for preclinical research. WFNOS 2022 Abstract Book (pp S65-S65), 24 March 2022 - 27 March 2022.
• Cottrell CM, Myers K, Dunning M, Bagga V, Sinha S, Al-Tamimi Y, Wang D, Rominiyi O & Collis S (2022) Development of unique ex vivo models of post-surgical residual glioblastoma. WFNOS 2022 Abstract Book (pp S219-S219), 24 March 2022 - 27 March 2022.
• Rominiyi O, Myers K, Gomez-Roman N, Jellinek DA, Chalmers AJ, Carroll TA, Chen B, Al-Tamimi Y & Collis S (2022) Combined inhibition of the Fanconi anaemia (FA) pathway and ATR promotes R-loop generation and profound radiosensitisation in glioblastoma. WFNOS 2022 Abstract Book (pp S253-S253), 24 March 2022 - 27 March 2022.
• Vanderlinden A, McGarrity-Cottrell C, Myers K, Carroll TA, Al-Tamimi Y, Rominiyi O & Collis S (2022) DNA damage response inhibitor combinations to enhance TTFields potency using clinically relevant ex-vivo glioblastoma models. WFNOS 2022 Abstract Book (pp S227-1), 24 March 2022 - 27 March 2022.
• Rominiyi O, Myers K, Vanderlinden A, Dar D, Bagga V, Gomez-Roman N, Jellinek D, Carroll T, Chalmers A, Al-Tamimi Y & Collis S (2019) EX-VIVO 3-DIMENSIONAL MODELS OF POST-SURGICAL RESIDUAL DISEASE IN HUMAN GLIOBLASTOMA. NEURO-ONCOLOGY, Vol. 21 (pp 271-271)
• Rominiyi O, Gomez-Roman N, Al-Tamimi Y, Jellinek DA, Chalmers AJ, Carroll TA, Chen B & Collis S (2018) FA-BASED COMBINATIONS TO TARGET THE DNA DAMAGE RESPONSE IN GLIOBLASTOMA. NEURO-ONCOLOGY, Vol. 20 (pp 358-358)
• Rominiyi O, Gomez-Roman N, Lad N, Al-Tamimi Y, Jellinek DA, Chalmers AJ, Carroll TA, Chen B & Collis SJ (2018) PRECLINICAL EVALUATION OF COMBINATIONS TARGETING THE DNA DAMAGE RESPONSE IN 2D AND 3D MODELS OF GLIOBLASTOMA STEM CELLS. NEURO-ONCOLOGY, Vol. 20 (pp 297-297)
• Marples B, Krueger SA, Wilson TG, Dabjan MB, Lee KC, Hymas RV, Wilson GD & Collis SJ (2016) Improving the Efficacy of Pulsed Radiation Therapy Using DNA Repair Inhibitors: A Preclinical Study. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol. 96(2) (pp E566-E567). Boston, Massachusetts, USA View this article in WRRO
• Alsobahi F, Collis S & Hunter K (2016) The role of Fanconi Anaemia pathway in sporadic non-FA associated head and neck squamous cell carcinoma. European Journal of Cancer, Vol. 61 (pp S35-S35)
• Patil AA, Hua P, Sellwood MA, Jellinek DA, Carroll TA, Chen B & Collis SJ (2015) IDENTIFICATION OF NOVEL SMALL MOLECULE INHIBITORS OF THE FANCONI ANAEMIA DNA REPAIR PATHWAY AS A MEANS TO SENSITISES GLIOBLASTOMAS TO CHEMOTHERAPEUTIC AGENTS. NEURO-ONCOLOGY, Vol. 17 (pp 20-20)
• DeWeese TL, Collis SJ, Lupold SE, Chowdury W, Kudrolli T, Swartz M & Rodriguez R (2007) Optimization of siRNA-transgene expression in adenoviral vector systems for radiation sensitizing strategies. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol. 69(3) (pp S595-S596)
• Collis SJ, Barber LJ, Martin JS, Ward JD & Boulton SJ (2006) HCLK2 couples FANCD2 to stalled replication forks and functions in the mammalian S-phase checkpoint. BREAST CANCER RESEARCH, Vol. 8 (pp S6-S6)

Preprints

• Derby S, Dutton L, Strathdee K, Stevenson K, Clough E, Koessinger A, Yu W, Tian Y, Gilmour L, McGhee E , McGarrity-Cottrell C et al (2023) Inhibition of ATR opposes glioblastoma invasion through disruption of cytoskeletal networks and integrin internalisation via macropinocytosis, Springer Science and Business Media LLC.
• Birch J, Strathdee K, Stevenson K, Derby S, Dutton L, Clough E, Koessinger A, Gilmour L, McGhee E, McGarrity-Cottrell C , Dibekeme AA et al (2021) Inhibition of ATR prevents macropinocytosis driven retraction of neurites and opposes invasion in GBM, Springer Science and Business Media LLC.
• O’Regan L, Barone G, Adib R, Woo CG, Jeong HJ, Richardson EL, Richards MW, Muller PAJ, Collis SJ, Fennell DA , Choi J et al (2019) EML4-ALK V3 drives cell migration through NEK9 and NEK7 kinases in non-small-cell lung cancer, Cold Spring Harbor Laboratory.
• O'Regan L, Barone G, Adib R, Woo CG, Jeong HJ, Richardson EL, Richards MW, Muller PAJ, Collis S, Fennell D , Choi J et al () EML4-ALK V3 Drives Cell Migration Through NEK9 and NEK7 Kinases in Non-Small-Cell Lung Cancer.